Treatment of pruritus of primary biliary cirrhosis with rifampin
The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Abstract
Pruritus can be a debilitating symptom in patients with chronic cholestasis. Based on previous reports of its efficacy, we evaluated the impact of rifampin on the pruritus associated with primary biliary cirrhosis. Fourteen patients were included in a randomized, crossover study. After a 15-day washout period, subjects were followed for three weeks. During the first and third week, patients received 600 mg of rifampin or placebo; no treatment was administered during the second week. Pruritus was subjectively scored on a scale from 0 to 100. With rifampin, pruritus disappeared in 11 patients and partially improved in three; with placebo, only two had a partial response (P less than 0.001). Six patients with a prior poor or no response to cholestyramine improved with rifampin. No changes in biochemical tests or side effects were observed during this period. We conclude that short-term administration of rifampin relieves pruritus in primary biliary cirrhosis. When administered over a period of eight months in an open study, the relief of pruritus was maintained, while one individual developed an allergic reaction. Rifampin appears to be a safe drug in the management of the pruritus of primary biliary cirrhosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although uncommon, drug-induced liver injuries-sometimes progressing to acute liver failure, hemolysis, renal impairment, and alteration in drug metabolism-have all been reported with rifampicin use such that use is avoided in patients with bilirubin levels greater than 2.5 mg/dL, with close follow-up warranted.(195,199)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [195]
In the citing paper
“Rifampicin, a pregnane X receptor agonist, has been used to successfully treat pruritus in patients with PBC in multiple small clinical trials at doses ranging from 150 mg daily to 300 mg twice daily.(193)(194)(195)(196)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [195]
In the citing paper
“Several prospective randomised placebo-controlled trials have shown rifampicin to be effective in the management of cholestatic pruritus.182–185”
From The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines (2018) · cites this paper as [184]
Citations
Cites
The two‐period cross‐over clinical trial.
Hills, M., & Armitage, P. (1979) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1979.tb05903.x · Cited by 1,395
(1959) · Postgraduate Medical Journal · doi:10.1136/pgmj.45.522.305-d · Cited by 497
THE ESTIMATION OF ANTIPYRINE IN BIOLOGICAL MATERIALS
Brodie, B. B., Axelrod, J., Soberman, R., & Levy, B. B. (1949) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)56807-1 · Cited by 409
Treatment of pruritus in primary biliary cirrhosis with rifampin
Ghent, C. N., & Carruthers, S. G. (1988) · Gastroenterology · doi:10.1016/0016-5085(88)90442-8 · Cited by 257
COMPARISON OF RIFAMPICIN WITH PHENOBARBITONE FOR TREATMENT OF PRURITUS IN BILIARY CIRRHOSIS
Bachs, L., Elena, M., Parés, A., Piera, C., & Rodés, J. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91608-5 · Cited by 231 · cited 7×
“Rifampin may rarely cause serious idiosyncratic hypersensitivity reactions, such as hemolytic anemia, renal failure, and thrombocytopenic purpura (9, 15-18).”
BackgroundInfluentialGrosset, J., & Leventis, S. (1983) · Clinical Infectious Diseases · doi:10.1093/clinids/5.supplement_3.s440 · Cited by 218 · cited 3×
“Up to 5% of individuals may have a moderate increase in transaminases, alkaline phosphatase, and bilirubin that normalize even in the presence of continued treatment (12).”
BackgroundRelief of the Pruritus of Jaundice with a Bile-Acid Sequestering Resin
Carey, J. B. (1961) · JAMA · doi:10.1001/jama.1961.03040180034008 · Cited by 133 · cited 1×
“H~-histamine blockers (2-5) or procedures such as plasmapheresis and phototherapy (6, 7).”
BackgroundScheuer, P. J., & Lefkowitch, J. H. (1995) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199511000-00018 · Cited by 130
Scheuer, P. J., Lal, S., Summerfield, J. A., & Sherlock, S. (1974) · The Lancet · doi:10.1016/s0140-6736(74)92381-2 · Cited by 120
Phenobarbital Effects in Cholestatic Liver Disease
BLOOMER, J. R., & BOYER, J. L. (1975) · Annals of Internal Medicine · doi:10.7326/0003-4819-82-3-310 · Cited by 120 · cited 1×
“H~-histamine blockers (2-5) or procedures such as plasmapheresis and phototherapy (6, 7).”
Background
Research works printed but not linked: 1
- Girling D: Hepatitis and other adverse reactions to antituberculous chemotherapy. Bull Int Union Tuber 51:8?12, 1980
Cited by
Kaplan, M. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702263160907 · Cited by 1,959
Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
(2011) · Encyclopedia of Cancer · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,240
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Metadata
- Authors
- Podesta, A., Lopez, P., Terg, R., Villamil, F., Flores, D., Mastai, R., Udaondo, C. B., & Companc, J. P.
- Affiliations
- Hospital Italiano de Buenos Aires (AR)
- Venue
- Digestive Diseases and Sciences
- Published
- 1991-02
- Volume
- 36
- Issue
- 2
- Pages
- 216-220
- ISSN
- 0163-2116 (ISSN-L)
- 1573-2568
- OpenAlex
- W2075314339
- Cited by
- 267
- References
- 31
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 6 · 2023: 6 · 2022: 6 · 2021: 6 · 2020: 5 · 2019: 6 · 2018: 9 · 2017: 12 · 2016: 9 · 2015: 14 · 2014: 8 · 2013: 6 · 2012: 9
- FWCI
- 5.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Digestive Diseases and Sciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- pruritus, primary biliary cirrhosis, rifampicin, cholestasis, cholestyramine, pruritus management, drug safety, allergic reactions
- MeSH terms
- Adult, Aged, Alkaline Phosphatase, Bilirubin, Female, Humans, Liver Cirrhosis, Biliary, Male, Middle Aged, Pruritus, Rifampin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.